Pfizer-BioNTech to supply EU with additional 200m doses of Covid-19 vaccine

(Sharecast News) - Pfizer and BioNTech have agreed to supply the European Union with an additional 200 million doses of their Covid-19 vaccine.
The European Commission also has an option to request the supply of an extra 100m doses, Pfizer said on Wednesday.

Pfizer-BioNTech had already committed to supplying 300m doses to the EU through 2021 under the first supply agreement signed last year. The additional 200m doses are expected to be delivered this year, with an estimated 75m due in the second quarter.

The total number of doses to be delivered to the EU member states by the end of 2021 is now 500m.

Pfizer chairman and chief executive officer Albert Bourla said: "We recognise that more people must be vaccinated as soon as possible to help defeat this virus and control the global pandemic. We are working relentlessly to support the further roll-out of vaccination campaigns in Europe and worldwide by expanding manufacturing capacity.

"With this new agreement with the European Commission, we now expect to deliver enough doses to vaccinate at least 250 million Europeans before the end of the year."

The Covid-19 vaccine made by the two companies is based on BioNTech proprietary mRNA technology. Biontech Se Adr